---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-033829"
form_type: "8-K"
ticker: "IMMX"
cik: "0001873835"
company_name: "Immix Biopharma, Inc."
filed_at: "2026-07-20T10:05:18+00:00"
generated_at: "2026-07-20T10:10:04.925080+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Immix Biopharma terminates Richard Graydon; management sees no material impact

## Summary
- Richard Graydon terminated effective July 17, 2026, for reasons unrelated to his company activities.
- Management states Graydon's short tenure means no material effect on the business.
- No replacement or further details on Graydon's role were disclosed in the filing.

## SEC filing metadata
- accession: 0001493152-26-033829
- form_type: 8-K
- ticker: IMMX
- cik: 0001873835
- company_name: Immix Biopharma, Inc.
- filed_at: 2026-07-20T10:05:18+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873835/000149315226033829/0001493152-26-033829-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873835/000149315226033829/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-033829
- JSON: https://secwatch.observer/filing/0001493152-26-033829.json
- Plain text: https://secwatch.observer/filing/0001493152-26-033829.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.